Navigation Links
Merck in the Dock Due To Vioxx

The Vioxx case takes a bad turn when the Texas jury awarded $32 million for the family of a 71-year-old man who had died after consuming the painkiller Vioxx. // But this will be greatly reduced by state law. The legal experts say that the verdict is a weak case against Vioxx maker Merck & Co. Inc.

The jury awarded Leonel Garza's family $7 million in compensatory damages for mental anguish and personal loss and $25 million in punitive damages, but the latter will be cut to no more than $750,000 because of a cap imposed by Texas law. Merck immediately said it would appeal the decision. It withdrew the $2.5 billion-a-year drug after it found that the use of Vioxx for more than 18 months doubled the risk of stroke and heart attack. Attorneys for Garza's family said that Vioxx caused blood clots that led to a fatal heart attack. They said Merck lied when it said only long-term use of Vioxx presented health dangers and accused the company of keeping the drug on the market long after learning of its risks because the New Jersey-based company needed the sales.

This led to the discovery that short-term use of Vioxx as a causative of heart attacks. Merck lawyers blamed Garza's death on heart disease that had plagued him since 1978. Merck attorney Richard Josephson said medical records indicate he may have taken Vioxx for only a week and stopped the medicine nearly three weeks before his death which shows that Vioxx was not involved in any way in Leonel Garza's death. But Kenneth Frazier, senior vice president and general counsel, told a conference call after the verdict that the company would fight each case and settle none.

Merck last year spent $285 million on legal fees related to Vioxx, and said its reserve fund for future litigation stood at $685 million at the end of 2005. Wall Street is watching the Vioxx trials closely for clues about how much the Vioxx issue ultimately will cost Merck. Shares of Merck closed down 26 cents at $34.74 on the New York Stock Exchange.


'"/>




Related medicine news :

1. E Merck introduces Livogen Z with zinc sulphate
2. Merck to pay $ 253.5 million to Vioxx victim family
3. Merck and Takeda to collaborate in the sale of Cancer drug Matuzumab
4. Judgment In Favor Of Merck For Vioxx Drug
5. Merck, ICMR to conduct joint trials on cervical cancer vaccine
6. Merck Says Januvia Effective In Type 2 Diabetes
7. Dr Reddys Launches Generic Version Of Mercks Proscar Tablets
8. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
9. Developing Nations to Get Gardasil at Lesser Rates from Merck Soon
10. Acid Test - Glaxos Cervarix, and Mercks Gardasil, Compete
11. Ranbaxy in Fray to Buy Mercks Generic Drugs Unit
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... ... February 11, 2016 , ... ... the American Academy of Dermatology Annual Meeting at the Walter E. Washington Convention ... raise awareness for both the condition of hyperhidrosis (excessive sweating) and its treatment ...
(Date:2/11/2016)... ... 11, 2016 , ... Husted Kicking has completed its Third Annual ... 6th & 7th, 2016 according to kicking coach Michael Husted. , “This event serves ... NFL’s combine in Indianapolis,” says Husted. “The NFL uses a third party organization to ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The book, ... for IT services, what questions to ask your IT consultant before signing a contract ... to your computer network. , “With companies relying heavily on e-mail and technology, it’s ...
(Date:2/11/2016)... ... , ... As part of their 2015 end of year funding strategy, ... has gifted $10,000 to University of Chicago to support ovarian cancer research being conducted ... are honored to support a promising young investigator from Dr. Lengyel’s lab at the ...
(Date:2/10/2016)... City, California (PRWEB) , ... February 10, 2016 ... ... Imaging Society (WMIS), known as the World Molecular Imaging Congress (WMIC), will be ... theme for the 2016 meeting is “Imaging Biology…Improving Therapy.” The congress will highlight ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... Feb. 11, 2016  Ampio Pharmaceuticals, Inc. (NYSE MKT: ... entered into a Controlled Equity Offering SM Sales ... Michael Macaluso , Chairman and CEO, stated "During ... are not currently raising money and that we have ... 2017 and still complete all of our current objectives ...
(Date:2/11/2016)... Germany , February 11, 2016 ... up 6.8% to EUR 1,377.2m  Adjusted EBITDA climbs to ... 18.0% to EUR 3.41  Proposed dividend of EUR 0.85 ... sale of glass tubing business and refinancing successfully completed  ... to 5% on organic basis  Adjusted EBITDA expected ...
(Date:2/10/2016)... REDWOOD CITY, Calif., Feb. 10, 2016   Genomic Health, Inc. ... progress for the quarter and year ended December 31, 2015. ... in the fourth quarter of 2015, compared with $69.1 million in ... a constant currency basis, revenue increased 9 percent compared with the ... --> U.S. revenue was $63.9 million in the fourth ...
Breaking Medicine Technology: